Page last updated: 2024-11-12
aplysin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
aplysin: Antineoplastic Agents, Alkylating, derived from Laurencia tristicha; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 11066347 |
CHEMBL ID | 463532 |
SCHEMBL ID | 10428585 |
MeSH ID | M000599148 |
Synonyms (17)
Synonym |
---|
6790-63-2 |
nsc-305227 |
aplysin |
inchi=1/c15h19bro/c1-9-7-13-11(8-12(9)16)14(3)6-5-10(2)15(14,4)17-13/h7-8,10h,5-6h2,1-4h3/t10-,14-,15-/m0/s |
CHEMBL463532 |
C17132 |
nsc 305227 |
j22ivp9vtm , |
unii-j22ivp9vtm |
1h-cyclopenta(b)benzofuran, 7-bromo-2,3,3a,8b-tetrahydro-3,3a,6,8b-tetramethyl-, (3s-(3alpha,3abeta,8bbeta))- |
SCHEMBL10428585 |
1h-cyclopenta(b)benzofuran, 7-bromo-2,3,3a,8b-tetrahydro-3,3a,6,8b-tetramethyl-, (3s,3as,8bs)- |
1h-cyclopenta(b)benzofuran, 7-bromo-2,3,3a,8b-tetrahydro-3,3a,6,8b-tetramethyl-, (3s-(3.alpha.,3a.beta.,8b.beta.))- |
(-)-aplysin |
aplysin, (-)- |
Q27281046 |
(3s,3as,8bs)-7-bromo-3,3a,6,8b-tetramethyl-2,3-dihydro-1h-cyclopenta[b][1]benzofuran |
Research Excerpts
Overview
Aplysin is a brominated sesquiterpene with an isoprene skeleton and has biological activities.
Excerpt | Reference | Relevance |
---|---|---|
"Aplysin is a brominated sesquiterpene with an isoprene skeleton and has biological activities. " | ( Aplysin Retards Pancreatic Necrosis and Inflammatory Responses in NOD Mice by Stabilizing Intestinal Barriers and Regulating Gut Microbial Composition. Chang, Z; Cui, X; Gao, MQ; Jiang, Y; Liang, H; Liu, Y; Xu, H; Xue, M, 2020) | 3.44 |
Actions
Excerpt | Reference | Relevance |
---|---|---|
"Aplysin was found to enhance the tumor-suppressing capacity of TRAIL on several TRAIL-resistant cancer cell lines." | ( Aplysin sensitizes cancer cells to TRAIL by suppressing P38 MAPK/survivin pathway. Lin, X; Liu, G; Liu, J; Ma, L; Wu, N; Zheng, L, 2014) | 2.57 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (5)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID402303 | Cytotoxicity against human Bel7402 cells by MTT assay | 2005 | Journal of natural products, Jun, Volume: 68, Issue:6 | Sesquiterpenes from the red alga Laurencia tristicha. |
AID402304 | Cytotoxicity against human HCT8 cells by MTT assay | 2005 | Journal of natural products, Jun, Volume: 68, Issue:6 | Sesquiterpenes from the red alga Laurencia tristicha. |
AID402305 | Cytotoxicity against human HeLa cells by MTT assay | 2005 | Journal of natural products, Jun, Volume: 68, Issue:6 | Sesquiterpenes from the red alga Laurencia tristicha. |
AID402302 | Cytotoxicity against human BGC823 cells by MTT assay | 2005 | Journal of natural products, Jun, Volume: 68, Issue:6 | Sesquiterpenes from the red alga Laurencia tristicha. |
AID402301 | Cytotoxicity against human A549 cells by MTT assay | 2005 | Journal of natural products, Jun, Volume: 68, Issue:6 | Sesquiterpenes from the red alga Laurencia tristicha. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (12)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (8.33) | 29.6817 |
2010's | 8 (66.67) | 24.3611 |
2020's | 3 (25.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 22.44
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.44) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |